Pharmaceutical Executive - Pharmaceutical news and analysis. Pharma management, sales, marketing & finance

ADVERTISEMENT

Previous Story Play / Pause Next Story
New & Noteworthy
Pre-emption and States' Rights
Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.
The Peace Dividend
A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.
WebMD: The Patient Value Equation
WebMD CEO David Schlanger tells PharmExec how connecting patients with physicians through a robust digital platform can deliver quality of care, cost savings, and better health outcomes.

Latest Pharm Exec Videos

Events
Facility Design, Innovation and Qualification
July 29, 2014 - July 31, 2014
Philadelphia, PA USA

Speed to Therapy
August 12, 2014 - August 13, 2014
Philadelphia, PA USA

8th Annual Forum on Transparency and Aggregate Spend
August 18, 2014 - August 20, 2014
Washington, DC USA

Catching Biopharmaceutical Sponsors by Surprise
Sandoz Wins Biosimilar Filing Race
Roche Reports Good Half-Year Performance
Pharm Exec's 2014 Dealmakers Outlook
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
European Pharma Races to Catch Up with Data Protection
Europe ReflectorBe Careful What You Wish For: EFPIA's Integrated Strategy Proposals
Drug Development Jill WechslerNIH Translational Research Partnership Yields Promising Therapy
From the Editor William LooneyBIO 2014's Surprising Takeaway: The Peace Dividend
Patient Advocacy Leela BarhamIndustry Challenged: Do More for Teenagers with Cancer
 More
Survey
The FDA Safety & Innovation Act (FDASIA) was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
16%
Protecting the supply chain
32%
Expedited reviews of drug submissions
16%
More stakeholder involvement
5%
View Results
PHARM EXEC GLOBAL DIGEST
Pharmaceutical Executive Digest EuropeTo read the latest issue of Pharm Exec Global Digest
Click here. Click here to receive the Digest into your inbox every month.
Click here